Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novo’s Business Plan For Tresiba Insulin Includes ‘Moderate’ Price Premium

Executive Summary

Reduced risk of hypoglycemia compared to competing long-acting insulin is not in Tresiba’s FDA label, at least not yet, but Novo Nordisk sees room for differentiation in duration and dosing flexibility.



Related Companies